Compound used to control cholesterol may also kill breast cancer
By ANIWednesday, February 23, 2011
WASHINGTON - A new University of Missouri study has found that a compound used to control cholesterol may also kill breast cancer cells.
Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center, and his research team discovered that a small molecule, Ro 48-8071, initially developed for controlling cholesterol synthesis ‘dramatically destroys’ human breast cancer cells.
This development was discovered as Hyder’s research team was investigating PRIMA-1, a drug that targets a common mutated gene in human breast cancer cells, and kills tumor cells.
During the course of the study, Xiaoquin Zou, of the MU Department of Physics and Astronomy, compared the chemistry of PRIMA-1 binding to thousands of proteins using a software program she developed called MDock.
Hyder and Zou found that PRIMA-1 showed excellent binding properties to a protein called oxidosqualene cyclase, (OSC) that is known to be important for producing cholesterol.
This led Hyder’s team to investigate whether known OSC inhibitors, such as Ro 48-8071, developed to stop cholesterol production, also killed breast cancer cells.
“We had been working with PRIMA-1 for some time, and what we didn’t quite understand is exactly how it killed tumor cells. With the current findings, we think it’s possible that one mechanism utilized by PRIMA-1 to kill cancer cells may include shutting down cholesterol synthesis, but we still don’t know for certain if that’s the case. What we do know is that Ro 48-8071 does stop cholesterol synthesis, and it proved to be just as effective in destroying cancer cells as PRIMA-1, without harming other normal breast cells, which is a big advantage,” said Hyder.
The findings have been published in the Journal of Molecular Graphics and Modelling. (ANI)
